Serum Institute produces over 100 million Covishield doses in June

The immunisation data published at 7 am on Sunday showed that India administered 6.4 million vaccine doses in a day

Covishield
Covishield (Photo: PTI)
Press Trust of India New Delhi
3 min read Last Updated : Jun 27 2021 | 6:09 PM IST

Fulfilling its commitment, Serum Institute of India has produced over 10 crore doses of its COVID-19 vaccine Covishield in June so far as India ramps up the pace of its vaccination drive in the face of a possible third wave of the viral infection.

India's Covid-19 inoculation drive has picked up pace under the new phase of universalisation of COVID-19 vaccination that commenced on June 21 with around 69 lakh vaccine doses being administered on an average daily in the last six days.

The immunisation data published at 7 am on Sunday showed that India administered 64.25 lakh vaccine doses in a day, taking the cumulative number of jabs given so far under the nationwide inoculation drive to 32.17 crore.

According to information provided to the Drugs Controller General of India (DCGI) by the Pune-based Serum Institute of India, it has sent 45 batches of Covishield, amounting to 10.80 crore doses, to the Central Drugs Laboratory, Kasauli for release in June so far.

The firm's Director at Government and Regulatory Affairs, Prakash Kumar Singh, had in May communicated to Union Home Minister Amit Shah that Covishield production would be ramped up to 10 crore doses in June.

"We are committed to enhancing the production capacity of our Covishield vaccine and have been working round-the-clock in spite of various challenges being faced by us because of COVID-19 pandemic.

"We are pleased to inform that in the month of June we will be able to manufacture and supply nine to 10 crore doses of our Covishield vaccine to our country as compared to our present production capacity of 6.5 crore doses in May," Singh had said in a communication to Shah.

The nationwide vaccination drive has been ramped up through availability of more vaccines, advance visibility of vaccine availability to states and Union Territories enabling them to plan better, streamlining the vaccine supply chain, according to the Health Ministry.

Under the revised guidelines, vaccine doses are provided free of cost by the Centre and are allocated to states and Union Territories based on criteria such as population, disease burden and the progress of vaccination. The Centre procures 75 per cent of the vaccines being produced in the country.

All above the age of 18 years are eligible for free vaccine doses.

The Centre had earlier allowed states and private hospitals to procure 50 per cent of the vaccines following demands for decentralisation of the process. However, after several states complained of problems including funding, Prime Minister Narendra Modi announced the revised vaccine guidelines.

In order to incentivise production and encourage new vaccines, domestic manufacturers are given the option to provide vaccines directly to private hospitals. This is restricted to 25 per cent of their monthly production under the new guidelines.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

First Published: Jun 27 2021 | 6:09 PM IST

Next Story